New Zealand Association of Cancer Specialists

If you are a member of the New Zealand Association of Cancer Specialists or related cancer interest group please register for an account so that you may access the restricted archives and participate in discussion surrounding current issues.

If you are a member of the public and find that the content on this site does not sufficiently answer questions you may have surrounding the NZACS or the treatment of cancer in New Zealand please see our list of related websites or contact us for further assistance. Please note that the NZACS is a professional association and that general questions about cancer and its treatment should be directed to organisations charged with promoting cancer awareness in the community.

Information on the New Zealand Cancer Research Coordinators Group

New Zealand Cancer Research Coordinators Group

2008 Special Interest Group Membership Application Form

The NZACS website hosts a number of Special Interest Groups that are open to non-NZACS members.  If you wish to apply to join one of these groups, please click the link and fill out the form. 

Joint Scientific Meeting

The Future of Oncology: Improving lives affected by cancer

Christchurch Convention Centre, New Zealand
6–9 August 2008

The Joint Scientific Meeting involves members from the:

Medical Oncology Group Australia
RANZCR Faculty of Radiation Oncology
New Zealand Society of Oncology
NZ Association of Cancer Specialists - NZACS

For more information please contact anzoncol@dcconferences.com.au. or go to http://dcconferences.com.au/anzoncol/

NZGCG Statement regarding HPV 16/18 vaccine funding

The New Zealand Gynaecological Cancer Group (NZGCG) is an independent multidisciplinary association of health professionals involved in the care of women with gynaecological cancer. The NZGCG is committed to improving outcomes from gynaecological cancer for all New Zealand women. The NZGCG supports public funding of HPV (Human Papilloma Virus) vaccination and its inclusion in the vaccination schedule.

It is known that infection with HPV types 16 and18 underlie about 70% of cervical cancers and a high proportion of vulval, vaginal and anal cancers. Vaccination of unexposed individuals almost eliminates the risk of persistent HPV infection and associated pre-cancerous abnormalities. Due to the long natural history of cervical cancer the impact of vaccination on cancer rates will take many years to document.

Very large trials of the HPV vaccine have been performed and published. There is no doubt we have available a safe vaccine that will significantly reduce the incidence of cervical cancer and its precursors as well as other HPV related anogenital disease.